<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:15:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4269343" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4269343</identifier>
        <datestamp>2015-03-24</datestamp>
        <setSpec>annonc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ann Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Ann. Oncol</journal-id>
              <journal-id journal-id-type="publisher-id">annonc</journal-id>
              <journal-id journal-id-type="hwp">annonc</journal-id>
              <journal-title-group>
                <journal-title>Annals of Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0923-7534</issn>
              <issn pub-type="epub">1569-8041</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4269343</article-id>
              <article-id pub-id-type="pmcid">PMC4269343</article-id>
              <article-id pub-id-type="pmc-uid">4269343</article-id>
              <article-id pub-id-type="pmid">25361981</article-id>
              <article-id pub-id-type="pmid">25361981</article-id>
              <article-id pub-id-type="doi">10.1093/annonc/mdu498</article-id>
              <article-id pub-id-type="publisher-id">mdu498</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Breast Tumors</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tobin</surname>
                    <given-names>N. P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harrell</surname>
                    <given-names>J. C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lövrot</surname>
                    <given-names>J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Egyhazi Brage</surname>
                    <given-names>S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Frostvik Stolt</surname>
                    <given-names>M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carlsson</surname>
                    <given-names>L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Einbeigi</surname>
                    <given-names>Z.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Linderholm</surname>
                    <given-names>B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                  <xref ref-type="aff" rid="mdu498_af4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loman</surname>
                    <given-names>N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Malmberg</surname>
                    <given-names>M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walz</surname>
                    <given-names>T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                  <xref ref-type="aff" rid="mdu498_af7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fernö</surname>
                    <given-names>M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perou</surname>
                    <given-names>C. M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bergh</surname>
                    <given-names>J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hatschek</surname>
                    <given-names>T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lindström</surname>
                    <given-names>L. S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="mdu498_af9">9</xref>
                  <xref ref-type="aff" rid="mdu498_af10">10</xref>
                  <xref ref-type="corresp" rid="mdu498_cor1">*</xref>
                </contrib>
                <on-behalf-of>for the TEX Trialists Group</on-behalf-of>
                <aff id="mdu498_af1"><label>1</label><addr-line>Department of Oncology and Pathology, Cancer Center Karolinska</addr-line>, <institution>Karolinska Institutet and University Hospital</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff>
                <aff id="mdu498_af2"><label>2</label><addr-line>Department of Genetics and Pathology, Lineberger Comprehensive Cancer Center</addr-line>, <institution>University of North Carolina-Chapel Hill</institution>, <addr-line>Chapel Hill</addr-line>, <country>USA</country></aff>
                <aff id="mdu498_af3"><label>3</label><addr-line>Department of Oncology</addr-line>, <institution>Sundsvall General Hospital</institution>, <addr-line>Sundsvall</addr-line></aff>
                <aff id="mdu498_af4"><label>4</label><addr-line>Department of Oncology</addr-line>, <institution>Sahlgrenska University Hospital</institution>, <addr-line>Gothenburg</addr-line></aff>
                <aff id="mdu498_af5"><label>5</label><addr-line>Department of Oncology</addr-line>, <institution>Skåne University Hospital</institution>, <addr-line>Lund</addr-line></aff>
                <aff id="mdu498_af6"><label>6</label><addr-line>Department of Oncology</addr-line>, <institution>Skåne University Hospital</institution>, <addr-line>Helsingborg</addr-line></aff>
                <aff id="mdu498_af7"><label>7</label><addr-line>Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences</addr-line>, <institution>Linköping University</institution>, <addr-line>Linköping</addr-line></aff>
                <aff id="mdu498_af8"><label>8</label><addr-line>Department of Clinical Sciences, Division of Oncology and Pathology</addr-line>, <institution>Lund University</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country></aff>
                <aff id="mdu498_af9"><label>9</label><addr-line>Department of Surgery</addr-line>, <institution>University of California at San Francisco (UCSF)</institution>, <addr-line>San Francisco</addr-line>, <country>USA</country></aff>
                <aff id="mdu498_af10"><label>10</label><addr-line>Department of Biosciences and Nutrition</addr-line>, <institution>Karolinska Institutet and University Hospital</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hatschek</surname>
                    <given-names>Thomas</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Fernö</surname>
                    <given-names>Mårten</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Lindström</surname>
                    <given-names>Linda Sofie</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hedenfalk</surname>
                    <given-names>Ingrid</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Brandberg</surname>
                    <given-names>Yvonne</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Carstensen</surname>
                    <given-names>John</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Egyhazy</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Stolt</surname>
                    <given-names>Marianne Frostvik</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Skoog</surname>
                    <given-names>Lambert</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Hellström</surname>
                    <given-names>Mats</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Maliniemi</surname>
                    <given-names>Maarit</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Svensson</surname>
                    <given-names>Helene</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Åström</surname>
                    <given-names>Gunnar</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Bergh</surname>
                    <given-names>Jonas</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Bjöhle</surname>
                    <given-names>Judith</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Lidbrink</surname>
                    <given-names>Elisabet</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Rotstein</surname>
                    <given-names>Sam</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Wallberg</surname>
                    <given-names>Birgitta</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Einbeigi</surname>
                    <given-names>Zakaria</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Carlsson</surname>
                    <given-names>Per</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Linderholm</surname>
                    <given-names>Barbro</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Walz</surname>
                    <given-names>Thomas</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Loman</surname>
                    <given-names>Niklas</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Malmström</surname>
                    <given-names>Per</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Söderberg</surname>
                    <given-names>Martin</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Malmberg</surname>
                    <given-names>Martin</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Carlsson</surname>
                    <given-names>Lena</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Umeå</surname>
                    <given-names/>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Lindh</surname>
                    <given-names>Birgitta</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Sundqvist</surname>
                    <given-names>Marie</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="collab">
                  <name>
                    <surname>Malmberg</surname>
                    <given-names>Lena</given-names>
                  </name>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="mdu498_cor1"><label>*</label><italic>Correspondence to:</italic> Dr Linda S. Lindström, Department of Biosciences and Nutrition, Karolinska Institutet and University Hospital, 141 83 Stockholm, Sweden. Tel: +46-72-536-50-18; E-mail: <email>linda.lindstrom@ki.se</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>1</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>10</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>31</day>
                <month>10</month>
                <year>2014</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>26</volume>
              <issue>1</issue>
              <fpage>81</fpage>
              <lpage>88</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>5</month>
                  <year>2014</year>
                </date>
                <date date-type="rev-recd">
                  <day>9</day>
                  <month>9</month>
                  <year>2014</year>
                </date>
                <date date-type="rev-recd">
                  <day>10</day>
                  <month>10</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>10</month>
                  <year>2014</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</copyright-statement>
                <copyright-year>2014</copyright-year>
                <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="mdu498.pdf"/>
              <abstract abstract-type="precis">
                <p>An enhanced understanding of the biology of breast cancer metastases is needed to individualize patient management. Here, we show that tumor characteristics of breast cancer metastases significantly influence post-relapse survival, emphasizing that molecular investigation at relapse offers clinically relevant information, with the potential to improve patient management and survival.</p>
              </abstract>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>We and others have recently shown that tumor characteristics are altered throughout tumor progression. These findings emphasize the need for re-examination of tumor characteristics at relapse and have led to recommendations from ESMO and the Swedish Breast Cancer group. Here, we aim to determine whether tumor characteristics and molecular subtypes in breast cancer metastases confer clinically relevant prognostic information for patients.</p>
                </sec>
                <sec>
                  <title>Patients and methods</title>
                  <p>The translational aspect of the Swedish multicenter randomized trial called TEX included 111 patients with at least one biopsy from a morphologically confirmed locoregional or distant breast cancer metastasis diagnosed from December 2002 until June 2007. All patients had detailed clinical information, complete follow-up, and metastasis gene expression information (Affymetrix array GPL10379). We assessed the previously published gene expression modules describing biological processes [proliferation, apoptosis, human epidermal receptor 2 (HER2) and estrogen (ER) signaling, tumor invasion, immune response, and angiogenesis] and pathways (Ras, MAPK, PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3, and β-catenin) and the intrinsic subtypes (PAM50). Furthermore, by contrasting genes expressed in the metastases in relation to survival, we derived a poor metastasis survival signature.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>A significant reduction in post-relapse breast cancer-specific survival was associated with low-ER receptor signaling and apoptosis gene module scores, and high AKT-MTOR, Ras, and β-catenin module scores. Similarly, intrinsic subtyping of the metastases provided statistically significant post-relapse survival information with the worst survival outcome in the basal-like [hazard ratio (HR) 3.7; 95% confidence interval (CI) 1.3–10.9] and HER2-enriched (HR 4.4; 95% CI 1.5–12.8) subtypes compared with the luminal A subtype. Overall, 25% of the metastases were basal-like, 32% HER2-enriched, 10% luminal A, 28% luminal B, and 5% normal-like.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>We show that tumor characteristics and molecular subtypes of breast cancer metastases significantly influence post-relapse patient survival, emphasizing that molecular investigations at relapse provide prognostic and clinically relevant information.</p>
                </sec>
                <sec>
                  <title>ClinicalTrials.gov</title>
                  <p>This is the translational part of the Swedish multicenter and randomized trial TEX, clinicaltrials.gov identifier nct01433614 (<uri xlink:type="simple" xlink:href="http://www.clinicaltrials.gov/ct2/show/nct01433614">http://www.clinicaltrials.gov/ct2/show/nct01433614</uri>).</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>breast cancer metastases</kwd>
                <kwd>metastasis characteristics</kwd>
                <kwd>TEX randomized trial</kwd>
                <kwd>gene expression</kwd>
                <kwd>gene modules</kwd>
                <kwd>biopsy at relapse</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="mdu498_s1">
              <title>introduction</title>
              <p>Breast cancer is widely recognized as a heterogeneous disease in the sense of both primary tumor metastatic capacity and time to metastatic spread of disease. Treatment with endocrine therapy is a major cornerstone in the management of breast cancer and has considerably improved patient survival. However, despite considerable progress, one of five women with early-stage breast cancer will later develop distant metastatic disease [<xref rid="MDU498C1" ref-type="bibr">1</xref>].</p>
              <p>We and others have recently shown that tumor characteristics are altered throughout tumor progression [<xref rid="MDU498C2" ref-type="bibr">2</xref>–<xref rid="MDU498C4" ref-type="bibr">4</xref>], which significantly influences patient survival [<xref rid="MDU498C2" ref-type="bibr">2</xref>, <xref rid="MDU498C5" ref-type="bibr">5</xref>]. These findings emphasize the need for re-examination of tumor characteristics at relapse to improve patient management and have led to recommendations from the ABC1, ASCO, ESMO, and Swedish Breast Cancer group (SweBCG), among others, regarding the re-evaluation of metastatic lesions for expression of estrogen (ER), progesterone (PR), and human epidermal receptor 2 (HER2) [<xref rid="MDU498C6" ref-type="bibr">6</xref>–<xref rid="MDU498C8" ref-type="bibr">8</xref>].</p>
              <p>Here, we aimed to enhance our understanding of the biology of breast cancer metastases in relation to post-relapse survival and to assess tumor characteristics with previously demonstrated prognostic significance in the primary tumor setting to understand their importance in metastatic disease. Our goal in doing so is to provide biologically relevant information that will help to guide individualized patient management. We analyzed tumor characteristics from one or more metastases of 111 breast cancer patients enrolled in the Swedish multicenter prospective and randomized TEX [Taxol<sup>®</sup> (paclitaxel): Bristol-Myers Squibb AB, Sweden; Farmorubicin® (epirubicin): Pfizer AB, Sweden; Xeloda® (capecitabine): Roche AB, Sweden] trial.</p>
            </sec>
            <sec sec-type="methods" id="mdu498_s2">
              <title>patients and methods</title>
              <p>The Swedish multicenter and randomized trial TEX [<xref rid="MDU498C9" ref-type="bibr">9</xref>], ClinicalTrials.gov identifier NCT01433614 (<uri xlink:type="simple" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01433614">http://www.clinicaltrials.gov/ct2/show/NCT01433614</uri>), enrolled 287 patients with a morphologically confirmed locoregional or distant breast cancer relapse from December 2002 until June 2007. Previous endocrine treatment of advanced disease in patients with hormone receptor-positive breast cancer was allowed. In addition, previous treatment with an anthracycline, a taxane, or 5-FU was allowed if the last course of chemotherapy was given at least 1 year before TEX study entry. Patients were randomly assigned to first-line chemotherapy with a combination of epirubicin and paclitaxel alone or in combination with capecitabine. Detailed clinical information and complete follow-up were available for all included patients.</p>
              <p>Patients with metastatic lesions accessible for either a fine-needle aspiration (FNA) or a core biopsy were asked to give a sample, but sampling was optional. We defined the site of relapse as the site where the metastatic biopsy was taken. The most common biopsy sites were lymph nodes (36.7%), liver (22.5%), skin (18.3%), and breast (15.8%). In total, tumor tissue was available from 149 of 287 patients.</p>
              <p>The translational aspect of the trial included 120 relapse biopsies (116 FNA biopsies and 4 core biopsies) from 111 patients yielding sufficient tumor RNA for gene expression profiling. The clinical and pathological patient characteristics of the translational TEX trial were representative of the original TEX trial.</p>
              <p>Details of the HRSTA-2.0 custom human Affymetrix array GPL10379 are available at NCBI GEO depository as GPL10379 (<uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL10379">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL10379</uri>). Briefly, this whole-genome array contains 52 378 individual probe sets, with each probe set containing 4–20 individual probes. The gene expression microarray data have been deposited into the Gene Expression Omnibus under the accession number of GSE56493.</p>
              <p>This study was approved by the Ethics committee at Karolinska Institutet and the other participating centers. All patients have given written informed consent.</p>
              <sec id="mdu498_s2a">
                <title>statistical methods</title>
                <sec id="mdu498_s2a1">
                  <title>preprocessing and normalization</title>
                  <p>The relapse tumor gene expression analyses were performed in the open-source software R using the aroma.affymetrix package [<xref rid="MDU498C10" ref-type="bibr">10</xref>]. Each gene expression array was individually background corrected and normalized using robust multichip averaging; no arrays were identified as having poor quality. The quality of the arrays was assessed utilizing Normalized Unscaled Standard Error plots and Relative Log Expression plots.</p>
                </sec>
                <sec id="mdu498_s2a2">
                  <title>survival analysis</title>
                  <p>Patient follow-up started at the date of the TEX study enrollment and ended at the date of death, or at the end of study follow-up, 1 July 2013. We carried out Kaplan–Meier and multivariate proportional hazard (Cox) analyses adjusting for calendar year and age at diagnosis in addition to the TEX clinical study treatment arms. We did not adjust for additional tumor characteristics due to sample size. The proportional hazard assumption for the main exposure variables was assessed including a time-dependent covariate in the survival model. No significant deviation was noted.</p>
                  <p>Breast cancer-specific survival was used as the end point. Post-relapse patient survival was defined as short-term (up to 1.5 years post-relapse survival) and long-term survival (up to 5 years or more). The short-term survival cutoff (1.5 years post-relapse survival) was defined retrospectively by applying a model of two normal distributions, in order to capture the visually apparent survival distribution, using the mixtools package in R [<xref rid="MDU498C11" ref-type="bibr">11</xref>]. A full description of this is provided in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Materials and methods, available at <italic>Annals of Oncology</italic> online</ext-link>.</p>
                </sec>
                <sec id="mdu498_s2a3">
                  <title>intrinsic subtype</title>
                  <p>We assessed the intrinsic subtypes (PAM50) for each relapse using the TEX metastasis gene expression arrays as previously described; full details are provided in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Materials and methods, available at <italic>Annals of Oncology</italic> online</ext-link> [<xref rid="MDU498C12" ref-type="bibr">12</xref>].</p>
                </sec>
                <sec id="mdu498_s2a4">
                  <title>gene modules</title>
                  <p>To characterize the tumor biology of the breast cancer relapses, we applied the set of 7 gene expression process modules and 10 pathway modules as previously described [<xref rid="MDU498C13" ref-type="bibr">13</xref>, <xref rid="MDU498C14" ref-type="bibr">14</xref>]. Each module is comprised of genes both positively and negatively associated with the gene of interest (e.g. <italic>ESR1</italic>) and the module as a whole is representative of a biological process/pathway. We computed the module score for every gene module in the relapses and divided the resulting continuous variables into tertiles as described in the original publications. The tertiles were grouped so that the most clinically aggressive tertile was compared with the remaining two.</p>
                  <p>Hierarchical clustering was used to indicate relapse sample similarity with respect to post-relapse survival (short- or long-term, see definition above) and relapse site.</p>
                </sec>
                <sec id="mdu498_s2a5">
                  <title>single probe association</title>
                  <p>Differential gene expression according to short- or long-term post-relapse patient survival (as defined above) was analyzed using the open-source R package OCplus 1.22.0 [<xref rid="MDU498C15" ref-type="bibr">15</xref>]. For additional information, see <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Methods, available at <italic>Annals of Oncology</italic> online</ext-link>.</p>
                  <p>All data preparation and analysis were done using SAS version 9.3 and R version 2.15.2.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="mdu498_s3">
              <title>results</title>
              <p>The clinico-pathological characteristics of the 111 patients included in the translational TEX trial are summarized in Table <xref rid="MDU498TB1" ref-type="table">1</xref>. The majority of patients were diagnosed with primary breast cancer from 1995 onwards and as expected from a clinically aggressive cohort, there were high numbers of ER negative (37.5%), PR negative (51.5%), grade 3 (52.4%), and stage IV (14.8%) tumors at primary tumor diagnosis. Metastatic sites were distributed as follows: breast (15.8%), liver (22.5%), lung/pleura (1.7%), lymph node (36.7%), skeleton (4.2%), skin (18.3%), and other 0.8%.<table-wrap id="MDU498TB1" position="float"><label>Table 1.</label><caption><p>Patient and tumor characteristics of the patients included in the translational TEX trial</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">Patients<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">Percent</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Age at primary tumor diagnosis, years</td></tr><tr><td rowspan="1" colspan="1"> &lt;45</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">24.3</td></tr><tr><td rowspan="1" colspan="1"> 45–55</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">40.5</td></tr><tr><td rowspan="1" colspan="1"> &gt;55</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">35.2</td></tr><tr><td colspan="3" rowspan="1">Calendar period of primary tumor diagnosis</td></tr><tr><td rowspan="1" colspan="1"> 1985–1989</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3.6</td></tr><tr><td rowspan="1" colspan="1"> 1990–1994</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">5.4</td></tr><tr><td rowspan="1" colspan="1"> 1995–1999</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">23.4</td></tr><tr><td rowspan="1" colspan="1"> 2000–2007</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">67.6</td></tr><tr><td colspan="3" rowspan="1">Primary tumor characteristics</td></tr><tr><td colspan="3" rowspan="1"> Estrogen receptor status</td></tr><tr><td rowspan="1" colspan="1">  Positive</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">62.5</td></tr><tr><td rowspan="1" colspan="1">  Negative</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">37.5</td></tr><tr><td rowspan="1" colspan="1">  Unknown</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1"> Progesterone receptor status</td></tr><tr><td rowspan="1" colspan="1">  Positive</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">48.5</td></tr><tr><td rowspan="1" colspan="1">  Negative</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">51.5</td></tr><tr><td rowspan="1" colspan="1">  Unknown</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1"> Elston–Ellis tumor grade</td></tr><tr><td rowspan="1" colspan="1">  1</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td rowspan="1" colspan="1">  2</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">42.7</td></tr><tr><td rowspan="1" colspan="1">  3</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">52.4</td></tr><tr><td rowspan="1" colspan="1">  Unknown</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1"> T stage at diagnosis</td></tr><tr><td rowspan="1" colspan="1">  T1</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">33.3</td></tr><tr><td rowspan="1" colspan="1">  T2</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">39.8</td></tr><tr><td rowspan="1" colspan="1">  T3</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">12.1</td></tr><tr><td rowspan="1" colspan="1">  T4</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">14.8</td></tr><tr><td rowspan="1" colspan="1">  Unknown</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1"> N stage at diagnosis</td></tr><tr><td rowspan="1" colspan="1">  N0</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">30.2</td></tr><tr><td rowspan="1" colspan="1">  N1</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">61.3</td></tr><tr><td rowspan="1" colspan="1">  N2</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">7.5</td></tr><tr><td rowspan="1" colspan="1">  N3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">  Unknown</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1"> M stage at diagnosis</td></tr><tr><td rowspan="1" colspan="1">  M0</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">76.6</td></tr><tr><td rowspan="1" colspan="1">  M1</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">23.4</td></tr><tr><td colspan="3" rowspan="1">Adjuvant therapy</td></tr><tr><td colspan="3" rowspan="1"> Endocrine therapy</td></tr><tr><td rowspan="1" colspan="1">  Yes</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">42.3</td></tr><tr><td rowspan="1" colspan="1">  No</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">57.7</td></tr><tr><td colspan="3" rowspan="1"> Radiotherapy</td></tr><tr><td rowspan="1" colspan="1">  Yes</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">57.7</td></tr><tr><td rowspan="1" colspan="1">  No</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">42.3</td></tr><tr><td colspan="3" rowspan="1"> Chemotherapy</td></tr><tr><td rowspan="1" colspan="1">  Yes</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">43.2</td></tr><tr><td rowspan="1" colspan="1">  No</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">56.8</td></tr></tbody></table></table-wrap></p>
              <sec id="mdu498_s3a">
                <title>gene expression modules of biological processes reflect the aggressive nature of breast cancer metastases</title>
                <p>To characterize the tumor biology of breast cancer metastases, we assessed a set of seven biologically relevant gene expression modules in our 120 metastatic samples [<xref rid="MDU498C13" ref-type="bibr">13</xref>]. For visualization purposes, we selected those genes positively correlated with each module from our samples and carried out hierarchical clustering (Figure <xref ref-type="fig" rid="MDU498F1">1</xref>A and B). All gene modules (AURKA—proliferation, CASP3—apoptosis, ERBB2—HER2 signaling, ESR1—ER signaling, PLAU—tumor invasion/metastasis, STAT1—immune response, and VEGF—angiogenesis) show a varying range of expression values emphasizing the biological diversity between metastases. The aggressive nature of these tumors is also readily apparent with the majority displaying high expression of genes related to proliferation (AURKA module) and approximately half exhibiting low <italic>ESR1</italic>-related expression (ESR1 module). The seven patients in our cohort with multiple gene expression arrays (either several biopsies on the same metastatic site or different sites) are indicted with colored arrows and numbers (Figure <xref ref-type="fig" rid="MDU498F1">1</xref>A, bottom of the heatmap). The paired metastases from four of seven patients cluster immediately beside one another (numbers 1, 4, 5, and 7). Conversely, three metastatic biopsy pairs from the same patient and relapse cluster separately (numbers 2, 3, and 6), indicating gene expression pattern differences between these intrarelapse tumor biopsies.
<fig id="MDU498F1" position="float"><label>Figure 1.</label><caption><p>Hierarchical clustering of gene expression profiles of breast cancer metastases based on module genes reflecting seven biological processes (A) Positively correlated module genes were selected for visual representation of 120 breast cancer metastatic samples. Arrows indicate patients with multiple metastases. AURKA, proliferation; CASP3, apoptosis; ERBB2, HER2 signaling; ESR1, estrogen signaling; PLAU, tumor invasion/metastasis; STAT1, immune response; VEGF, angiogenesis. (B) Zoom-in of CASP3 and VEGF modules.</p></caption><graphic xlink:href="mdu49801"/></fig></p>
              </sec>
              <sec id="mdu498_s3b">
                <title>low ESR1 and CASP3 gene module scores are associated with poor post-relapse survival</title>
                <p>Long- and short-term Kaplan–Meier survival curves for the ESR1 and CASP3 gene modules are shown in Figure <xref ref-type="fig" rid="MDU498F2">2</xref> A and B, (left panels, and for the remaining modules in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Figures S1 and S2, available at <italic>Annals of Oncology</italic> online</ext-link>. Patients with a low CASP3 module score demonstrated poor long-term survival relative to those with an intermediate/high score (Figure <xref ref-type="fig" rid="MDU498F2">2</xref>B, left panel, <italic>P</italic> = 0.0010). In addition, low ESR1 and CASP3 module scores were associated with poor short-term breast cancer-specific survival (Figure <xref ref-type="fig" rid="MDU498F2">2</xref>A and B, right panels, <italic>P</italic> = 0.0078 and <italic>P</italic> = 0.045, respectively). Furthermore, using a multivariate proportional hazard (Cox) model adjusting for age at diagnosis, diagnosis date, and TEX clinical study treatment received, a more than twofold increased risk for death from breast cancer (short-term survival) was found in patients whose tumors had low CASP3 and ESR1 module scores [hazard ratio (HR) 2.2; 95% confidence interval (CI) 1.1–4.1 and 2.2; 95% CI 1.2–4.2, respectively], see Table <xref rid="MDU498TB2" ref-type="table">2</xref> (significant risk estimates in bold) and <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Figures S1 and S2, available at <italic>Annals of Oncology</italic> online</ext-link>.<table-wrap id="MDU498TB2" position="float"><label>Table 2.</label><caption><p>Multivariate analysis of gene modules and subtypes in relation to patient post-relapse survival</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Long-term breast cancer-specific survival<hr/></th><th align="center" colspan="3" rowspan="1">Short-term breast cancer-specific survival<sup><sup>b</sup></sup><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">HR</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="left" rowspan="1" colspan="1">HR</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">Module<sup>a</sup> (<italic>n</italic> = 111)</td></tr><tr><td rowspan="1" colspan="1"> ESR1 low<sup>c</sup></td><td rowspan="1" colspan="1">1.3</td><td rowspan="1" colspan="1">0.8–2.1</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1"><bold>2.2</bold></td><td rowspan="1" colspan="1"><bold>1.2–4.2</bold></td><td rowspan="1" colspan="1"><bold>0.01</bold></td></tr><tr><td rowspan="1" colspan="1"> ERBB2 high<sup><sup>d</sup></sup></td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.5–1.4</td><td rowspan="1" colspan="1">0.46</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.4–1.5</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1"> AURKA high<sup><sup>d</sup></sup></td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">0.8–2.0</td><td rowspan="1" colspan="1">0.38</td><td rowspan="1" colspan="1">1.1</td><td rowspan="1" colspan="1">0.5–2.1</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1"> PLAU high<sup><sup>d</sup></sup></td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">0.7–1.9</td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">0.8–2.7</td><td rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="1" colspan="1"> VEGF low<sup>c</sup></td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">0.6–1.6</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">0.8–2.8</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1"> STAT1 low<sup>c</sup></td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">0.6–1.6</td><td rowspan="1" colspan="1">0.99</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">0.4–1.6</td><td rowspan="1" colspan="1">0.58</td></tr><tr><td rowspan="1" colspan="1"> CASP3 low<sup>c</sup></td><td rowspan="1" colspan="1"><bold>2.7</bold></td><td rowspan="1" colspan="1"><bold>1.7–4.5</bold></td><td rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td rowspan="1" colspan="1"><bold>2.2</bold></td><td rowspan="1" colspan="1"><bold>1.1–4.1</bold></td><td rowspan="1" colspan="1"><bold>0.02</bold></td></tr><tr><td colspan="7" rowspan="1">PAM50<sup>a</sup> (<italic>n</italic> = 105)</td></tr><tr><td rowspan="1" colspan="1"> Luminal A (Ref.)</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">1.0</td><td rowspan="1" colspan="1">–</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> Luminal B</td><td rowspan="1" colspan="1">2.3</td><td rowspan="1" colspan="1">0.8–6.9</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">2.4</td><td rowspan="1" colspan="1">0.3–19.5</td><td rowspan="1" colspan="1">0.42</td></tr><tr><td rowspan="1" colspan="1"> HER2-enriched</td><td rowspan="1" colspan="1"><bold>4.4</bold></td><td rowspan="1" colspan="1"><bold>1.5–12.8</bold></td><td rowspan="1" colspan="1"><bold>0.01</bold></td><td rowspan="1" colspan="1"><bold>7.6</bold></td><td rowspan="1" colspan="1"><bold>1.0–58.2</bold></td><td rowspan="1" colspan="1"><bold>0.05</bold></td></tr><tr><td rowspan="1" colspan="1"> Basal-like</td><td rowspan="1" colspan="1"><bold>3.7</bold></td><td rowspan="1" colspan="1"><bold>1.3–10.9</bold></td><td rowspan="1" colspan="1"><bold>0.02</bold></td><td rowspan="1" colspan="1"><bold>7.2</bold></td><td rowspan="1" colspan="1"><bold>1.0–54.6</bold></td><td rowspan="1" colspan="1"><bold>0.06</bold></td></tr></tbody></table><table-wrap-foot><fn id="TN13"><p><sup>a</sup>Adjusted for age at diagnosis, diagnosis date, and treatment received.</p></fn><fn id="TN14"><p><sup>b</sup>1.5-year survival.</p></fn><fn id="TN15"><p><sup>c</sup>Intermediate/high as reference group.</p></fn><fn id="TN16"><p><sup>d</sup>Low/intermediate as reference group.</p></fn><fn id="TN17"><p>HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
<fig id="MDU498F2" position="float"><label>Figure 2.</label><caption><p>Long- and short-term breast cancer-specific post-relapse survival in relation to gene module groups (A) ESR1 module tertiles long-term (5 years) and short-term (1.5 years) breast cancer-specific survival, respectively. (B) CASP3 module tertiles long- and short-term post-relapse survival, respectively. A <italic>P</italic> value is based on the log-ranked test, and numbers at risk are shown underneath each graph.</p></caption><graphic xlink:href="mdu49802"/></fig></p>
              </sec>
              <sec id="mdu498_s3c">
                <title>gene module scores representative of the AKT-MTOR, RAS, and BETA-C signaling pathways are associated with poor post-relapse survival</title>
                <p>To further characterize the biology of our metastatic samples, we extended our gene module analysis to include a set of 10 previously described biologically relevant signaling pathways (Ras, MAPK, PTEN, AKT-MTOR, PI3KCA, IGF1, Src, Myc, E2F3, and β-catenin) [<xref rid="MDU498C14" ref-type="bibr">14</xref>]. In summary, high AKT-MTOR (<italic>P</italic> log rank = 0.03, HR 1.7; 95% CI 1.1–2.7), RAS (<italic>P</italic> log rank = 0.03, HR 1.8, 95% CI 1.1–2.9), and BETA-C (P log rank = 0.03, HR 1.7, 95% CI 1.1–2.7) module scores were significantly associated with long-term poor post-relapse survival (<ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Figures S3–S6, available at <italic>Annals of Oncology</italic> online</ext-link>).</p>
              </sec>
              <sec id="mdu498_s3d">
                <title>breast cancer molecular subtypes of metastases provide information of post-relapse survival</title>
                <p>Overall, 25% of the metastases were basal-like (<italic>n</italic> = 30), 32% HER2-enriched (<italic>n</italic> = 38), 10% luminal A (<italic>n</italic> = 12), 28% luminal B (<italic>n</italic> = 34), and 5% normal-like. These subtypes were significantly associated with survival in the Kaplan–Meier analysis (<italic>P</italic> = 0.008, Figure <xref ref-type="fig" rid="MDU498F3">3</xref>A) with the shortest survival seen in the basal-like and HER2-enriched subgroups. Furthermore, using a multivariate proportional hazard (Cox) model adjusting for age at diagnosis, diagnosis date, and TEX clinical study treatment received, a more than threefold increased risk for death from breast cancer was found in patients whose tumors were basal-like and HER2-enriched (HR 3.7; 95% CI 1.3–10.9 and 4.4; 95% CI 1.5–12.8, respectively), see Table <xref rid="MDU498TB2" ref-type="table">2</xref>.
<fig id="MDU498F3" position="float"><label>Figure 3.</label><caption><p>The PAM50 intrinsic subtypes in relation to long- and short-term post-relapse breast cancer-specific survival. (A) The PAM50 intrinsic subtypes in relation to long-term (5 years) breast cancer-specific survival. (B) The PAM50 intrinsic subtypes in relation to short-term (1.5 years) breast cancer-specific survival. A <italic>P</italic> value is based on log-ranked test, and numbers at risk are shown underneath each graph.</p></caption><graphic xlink:href="mdu49803"/></fig></p>
              </sec>
              <sec id="mdu498_s3e">
                <title>basal-like, cell cycle, and mesenchymal-related genes are upregulated in patients with short-term post-relapse survival</title>
                <p>Finally, in an effort to understand genetic differences between tumors of patients with short-term versus long-term survival, we carried out differential gene expression analysis to identify a poor metastasis survival signature. The poor metastasis survival signature included 136 unique genes differentially expressed between patients with short-term compared with long-term post-relapse survival. The expression of the included genes is presented in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Figure S7, available at <italic>Annals of Oncology</italic> online</ext-link> and the full gene list is also provided in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Table S1, available at <italic>Annals of Oncology</italic> online</ext-link>. Strikingly, patients with short-term survival (<ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Figure S7, available at <italic>Annals of Oncology</italic> online</ext-link>, red in the horizontal sidebar) displayed increased expression of the epithelial to mesenchymal marker <italic>SNAI1</italic>, the cell cycle markers <italic>CCNE1</italic>, <italic>CDC25B</italic>, and the basal/triple-negative-associated gene <italic>CAV2</italic>. Moreover, the same patients showed reduced expression of the <italic>ESR1</italic>, <italic>GATA3</italic>, and <italic>FOXA1</italic> genes, all of which are linked to a luminal breast phenotype and ER receptor expression. A gene ontology analysis of these 136 genes is also provided in <ext-link ext-link-type="uri" xlink:href="http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdu498/-/DC1">supplementary Table S2, available at <italic>Annals of Oncology</italic> online</ext-link>. These results are in line with our earlier findings, showing a worse survival outcome in patients with a low ESR1 module score and basal-like subtype.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="mdu498_s4">
              <title>discussion</title>
              <p>It is now accepted that standard breast cancer markers alter their expression throughout tumor progression [<xref rid="MDU498C2" ref-type="bibr">2</xref>–<xref rid="MDU498C5" ref-type="bibr">5</xref>], which significantly influences patient survival [<xref rid="MDU498C2" ref-type="bibr">2</xref>, <xref rid="MDU498C5" ref-type="bibr">5</xref>]. As such, investigation of tumor characteristics at relapse has the potential to improve patient management and survival. However, in order to be able to further individualize patient management in the metastatic setting, we need a better understanding of the association between metastatic tumor characteristics and patient survival. If tumor aggressiveness as assessed by the prognostic markers in the primary setting can be translated to the metastatic setting, this information would be clinically relevant.</p>
              <p>To enhance our current understanding of tumor biology in breast cancer metastases, we analyzed the TEX randomized trial that included 111 patients with available gene expression information from one or more metastatic lesions. Specifically, we assessed gene modules representative of tumor biological processes and pathways, as well as, the intrinsic subtypes [<xref rid="MDU498C12" ref-type="bibr">12</xref>], in all metastatic samples and related our findings to patient survival. Interestingly, a significant reduction in post-relapse breast cancer-specific survival was demonstrated for patients with the lowest levels of ER receptor signaling (ESR1 module) and apoptosis (CASP3). Furthermore, high AKT-MTOR, RAS, as well as BETA-C (β-catenin) signaling were significantly associated with poor post-relapse survival. Similarly, the intrinsic subtypes in the metastases provided statistically significant post-relapse survival information, with the worst survival outcome in the basal-like and HER2-enriched subtypes. Additionally, patients with poor post-relapse survival showed high metastasis expression levels of basal-like, cell cycle, and mesenchymal-related genes with concomitant low expression of luminal genes.</p>
              <p>While little is known about the biology of breast cancer metastases themselves, the steps governing the progression from primary breast tumor to seeding of distant metastatic lesions has been a focal point of intense investigation (for review see refs. [<xref rid="MDU498C16" ref-type="bibr">16</xref>, <xref rid="MDU498C17" ref-type="bibr">17</xref>]). These steps comprise what is typically termed ‘the metastatic cascade’ and consist of invasion/proliferation into the tissue surrounding the primary tumor, intravasation to blood or lymph vessels, extravasation to distal organs, and finally colonization of the distant tumor microenvironment. With regard to colonization, one of the main processes that have been hypothesized as essential to the successful development of metastatic breast tumors is cell proliferation [<xref rid="MDU498C17" ref-type="bibr">17</xref>]. Through application of the AURKA gene module, we demonstrate that the vast majority of our samples are highly proliferative; this finding is also supported by the intrinsic subtypes where the majority of tumors are luminal B, HER2-enriched, and basal-like subtypes—all of which are associated with high levels of proliferation. Of note, the luminal A subtype of tumors that are known to display lower levels of proliferation have the best post-relapse survival in our dataset [<xref rid="MDU498C18" ref-type="bibr">18</xref>]. These results may emphasize the importance of proliferation in relation to survival in metastatic tumors, at least in tumors of luminal subtype, and indicate that a routinely employed proliferative marker, such as Ki-67, could also prove informative in a clinical setting.</p>
              <p>In conclusion, an enhanced understanding of the biology of breast cancer metastases is needed to improve both patient survival in the metastatic setting and prediction of which patients are at high risk to later develop metastatic breast cancer disease. We show that the tumor characteristics of metastases significantly influence post-relapse patient survival emphasizing that molecular investigation at relapse offers clinically relevant information, with the potential to improve patient management and survival in the relapse setting.</p>
            </sec>
            <sec id="mdu498_s5">
              <title>funding</title>
              <p>This work was supported by the <funding-source id="cs1" rid="cn1">Swedish Research Council</funding-source> (grant no: <award-id id="cn1" rid="cs1">524-2011-6857</award-id> and 521-2014-2057 to LSL), the <funding-source id="cs2" rid="cn2">Swedish Research Council for Health, Working life and Welfare, FORTE</funding-source> (grant no: <award-id id="cn2" rid="cs2">2014-1962</award-id> to LSL), the Swedish Cancer Society, the Cancer Society in Stockholm, the King Gustaf V Jubilee Foundation, the Swedish Breast Cancer Association (BRO), and the Swedish Research Council to JB and unrestricted grants from Bristol-Myers Squibb Sweden AB, Pfizer Sweden AB, and Roche Sweden AB. The gene expression profiling was carried out by Merck at the former Rosetta facility. CMP and JCH were supported by funds from the <funding-source id="cs3" rid="cn3">NCI Breast SPORE program</funding-source> (<award-id id="cn3" rid="cs3">P50-CA58223-09A1</award-id>), and the Breast Cancer Research Foundation (CMP).</p>
            </sec>
            <sec id="mdu498_s6">
              <title>disclosure</title>
              <p>JB receives research funding from Merck, Amgen, Roche, Sanofi-Aventis and Bayer, paid to Karolinska University Hospital. CMP is an equity stock holder, and Board of Director Member, of BioClassifier LLC and University Genomics. CMP is also listed as an inventor on a patent application on the PAM50 molecular assay. All remaining authors have declared no conflicts of interest.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplementary Data</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_26_1_81__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_figs.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_table1.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_table2.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_data.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_fig.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_tables1.docx"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_mdu498_mdu498supp_tables2.docx"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>acknowledgements</title>
              <p>The TEX Trialists Group: Coordinating Investigator: Thomas Hatschek; Translational research: Mårten Fernö, Linda Sofie Lindström, and Ingrid Hedenfalk; HRQoL: Yvonne Brandberg; Statistics: John Carstensen; Laboratory: Suzanne Egyhazy, Marianne Frostvik Stolt, and Lambert Skoog; Clinical Trial Office: Mats Hellström, Maarit Maliniemi, and Helene Svensson; Radiology: Gunnar Åström; Karolinska University Hospital, Stockholm: Jonas Bergh, Judith Bjöhle, Elisabet Lidbrink, Sam Rotstein, and Birgitta Wallberg; Sahlgrenska University Hospital, Gothenburg: Zakaria Einbeigi, Per Carlsson, and Barbro Linderholm; Linköping University Hospital: Thomas Walz; Skåne University Hospital Lund/Malmö: Niklas Loman, Per Malmström, and Martin Söderberg; Helsingborg General Hospital: Martin Malmberg; Sundsvall General Hospital: Lena Carlsson; Umeå University Hospital: Birgitta Lindh; Kalmar General Hospital: Marie Sundqvist; Karlstad General Hospital: Lena Malmberg</p>
            </ack>
            <ref-list>
              <title>references</title>
              <ref id="MDU498C1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Godwin</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <collab>Early Breast Cancer Trialists' Collaborative Group (EBCTCG)</collab>
                  <article-title>Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials</article-title>
                  <source>Lancet</source>
                  <year>2011</year>
                  <volume>378</volume>
                  <issue>9793</issue>
                  <fpage>771</fpage>
                  <lpage>784</lpage>
                  <pub-id pub-id-type="pmid">21802721</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lindstrom</surname>
                      <given-names>LS</given-names>
                    </name>
                    <name>
                      <surname>Karlsson</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wilking</surname>
                      <given-names>UM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression</article-title>
                  <source>J Clin Oncol</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <issue>21</issue>
                  <fpage>2601</fpage>
                  <lpage>2608</lpage>
                  <pub-id pub-id-type="pmid">22711854</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Niikura</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hayashi</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>30</volume>
                  <issue>6</issue>
                  <fpage>593</fpage>
                  <lpage>599</lpage>
                  <pub-id pub-id-type="pmid">22124109</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amir</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Geddie</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>30</volume>
                  <issue>6</issue>
                  <fpage>587</fpage>
                  <lpage>592</lpage>
                  <pub-id pub-id-type="pmid">22124102</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thompson</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Jordan</surname>
                      <given-names>LB</given-names>
                    </name>
                    <name>
                      <surname>Quinlan</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)</article-title>
                  <source>Breast Cancer Res</source>
                  <year>2010</year>
                  <volume>12</volume>
                  <issue>6</issue>
                  <fpage>R92</fpage>
                  <pub-id pub-id-type="pmid">21059212</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cardoso</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Fallowfield</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Costa</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>
                  <source>Ann Oncol</source>
                  <year>2011</year>
                  <volume>22</volume>
                  <issue>Suppl 6</issue>
                  <fpage>vi25</fpage>
                  <lpage>vi30</lpage>
                  <pub-id pub-id-type="pmid">21908499</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wolff</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Hammond</surname>
                      <given-names>MEH</given-names>
                    </name>
                    <name>
                      <surname>Hicks</surname>
                      <given-names>DG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update</article-title>
                  <source>J Clin Oncol</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>31</issue>
                  <fpage>3997</fpage>
                  <lpage>4013</lpage>
                  <pub-id pub-id-type="pmid">24101045</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cardoso</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Costa</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Norton</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>1st International consensus guidelines for advanced breast cancer (ABC 1)</article-title>
                  <source>Breast</source>
                  <year>2012</year>
                  <volume>21</volume>
                  <issue>3</issue>
                  <fpage>242</fpage>
                  <lpage>252</lpage>
                  <pub-id pub-id-type="pmid">22425534</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hatschek</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Carlsson</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Einbeigi</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial</article-title>
                  <source>Breast Cancer Res Treat</source>
                  <year>2012</year>
                  <volume>131</volume>
                  <issue>3</issue>
                  <fpage>939</fpage>
                  <lpage>947</lpage>
                  <pub-id pub-id-type="pmid">22094937</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C10">
                <label>10</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bengtsson</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Simpson</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Bullard</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <source>Aroma. Affymetrix: A Generic Framework in R for Analyzing Small to Very Large Affymetrix Data Sets in Bounded Memory</source>
                  <year>2008</year>
                  <publisher-loc>Berkeley</publisher-loc>
                  <publisher-name>Department of Statistics, University Of California, Berkeley</publisher-name>
                </element-citation>
              </ref>
              <ref id="MDU498C11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Benaglia</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Chauveau</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hunter</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>DS</given-names>
                    </name>
                  </person-group>
                  <article-title>Mixtools: an R package for analyzing finite mixture models</article-title>
                  <source>J Stat Softw</source>
                  <year>2009</year>
                  <volume>32</volume>
                  <issue>6</issue>
                  <fpage>1</fpage>
                  <lpage>29</lpage>
                </element-citation>
              </ref>
              <ref id="MDU498C12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parker</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Mullins</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cheang</surname>
                      <given-names>MCU</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>8</issue>
                  <fpage>1160</fpage>
                  <lpage>1167</lpage>
                  <pub-id pub-id-type="pmid">19204204</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Desmedt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Haibe-Kains</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Wirapati</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2008</year>
                  <volume>14</volume>
                  <issue>16</issue>
                  <fpage>5158</fpage>
                  <lpage>5165</lpage>
                  <pub-id pub-id-type="pmid">18698033</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ignatiadis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Singhal</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Desmedt</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis</article-title>
                  <source>J Clin Oncol</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <issue>16</issue>
                  <fpage>1996</fpage>
                  <lpage>2004</lpage>
                  <pub-id pub-id-type="pmid">22508827</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C15">
                <label>15</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pawitan</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Ploner</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <source>OCplus: Operating Characteristics Plus Sample Size and Local fdr for Microarray Experiments</source>
                  <comment>R package version 1.40.0</comment>
                </element-citation>
              </ref>
              <ref id="MDU498C16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shibue</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment</article-title>
                  <source>Semin Cancer Biol</source>
                  <year>2011</year>
                  <volume>21</volume>
                  <issue>2</issue>
                  <fpage>99</fpage>
                  <lpage>106</lpage>
                  <pub-id pub-id-type="pmid">21145969</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Valastyan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Weinberg</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title>
                  <source>Cell</source>
                  <year>2011</year>
                  <volume>147</volume>
                  <issue>2</issue>
                  <fpage>275</fpage>
                  <lpage>292</lpage>
                  <pub-id pub-id-type="pmid">22000009</pub-id>
                </element-citation>
              </ref>
              <ref id="MDU498C18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cheang</surname>
                      <given-names>MCU</given-names>
                    </name>
                    <name>
                      <surname>Chia</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Voduc</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer</article-title>
                  <source>JNCI J Natl Cancer Inst</source>
                  <year>2009</year>
                  <volume>101</volume>
                  <issue>10</issue>
                  <fpage>736</fpage>
                  <lpage>750</lpage>
                  <pub-id pub-id-type="pmid">19436038</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
